Tumor Lysis Syndrome Following PSMA Radioligand Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39365095.
- Also identified by DOI 10.1097/RLU.0000000000005445.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor lysis syndrome (TLS) is a rare complication following treatment in prostate cancer patients. We present a 65-year-old man with history of castration-resistant prostate cancer who developed TLS following 2 sessions of 177 Lu-PSMA therapy. The patient presented with bulky axillary and mediastinal lymphadenopathies, an unusual site for prostate cancer metastasis. Although his PSA levels declined following treatment, he reported excessive weakness leading to immobility. Laboratory correlation showed markedly increased lactate dehydrogenase, from 413 to 543,000 U/L, suggesting the occurrence of TLS. Although being considered a relatively safe treatment, 177 Lu-PSMA can sometime lead to life-threatening events, which is reviewed here.
Medical subject headings
- Tumor Lysis Syndrome